Thrombospondin-1 modulates the angiogenic phenotype of human cerebral arteriovenous malformation endothelial cells

Neurosurgery

Volumn 68, Issue 5, 2011, Pages 1342-1353

  Stapleton, Christopher J ^a,b   Armstrong, Don L ^a   Zidovetzki, Raphael ^c   Liu, Charles Y ^a,d   Giannotta, Steven L ^a   Hofman, Florence M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d California Institute of Technology   (United States)

Author keywords

Angiogenesis; Cerebral arteriovenous malformations; Endothelium; Inhibitor of DNA binding differentiation 1; Thrombospondin 1

Indexed keywords

ENDOTHELIN 1; INTERLEUKIN 8; MESSENGER RNA; SMALL INTERFERING RNA; THROMBOSPONDIN 1; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; ANGIOGENESIS; ARTICLE; BRAIN ARTERIOVENOUS MALFORMATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; NEUROBIOLOGY; NEUROMODULATION; NEUROPATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

ADULT; ANGIOGENIC PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; HUMANS; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; THROMBOSPONDIN 1; YOUNG ADULT;

EID: 79954986892     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e31820c0a68     Document Type: Article

References (56)

1. Friedlander RM. Arteriovenous malformations ofthe brain. N Engl J Med. 2007;356(26):2704-2712.
2. Stapf C, Mast H, Sciacca RR, et al. Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology. 2006;66(9):1350- 1355. (Pubitemid 43739643)
3. Hartmann A, Pile-Spellman J, Stapf C, et al. Risk of endovascular treatment of brain arteriovenous malformations. Stroke. 2002;33(7):1816-1820. (Pubitemid 34761067)
4. Haw CS, terBrugge K, Willinsky R, Tomlinson G. Complications of embolization of arteriovenous malformations ofthe brain. J Neurosurg. 2006;104(2):226-232.
5. Berman MF, Sciacca RR, Pile-Spellman J, et al. The epidemiology of brain arteriovenous malformations. Neurosurgery. 2000;47(2):389-397. (Pubitemid 32049345)
6. Stapf C, Mast H, Sciacca RR, et al. The New York Islands AVM Study: design, study progress, and initial results. Stroke. 2003;34(5):e29-e33.
7. Stapf C, Mohr JP. Unruptured brain arteriovenous malformations should be treated conservatively: yes. Stroke. 2007;38(12):3308-3309.
8. Lawton MT, Du R, Tran MN, et al. Effect ofpresenting hemorrhage on outcome after microsurgical resection of brain arteriovenous malformations. Neurosurgery. 2005;56(3):485-493.
9. Spetzler RF, Martin NA. A proposed grading system for arteriovenous malfor-mations. J Neurosurg. 1986;65(4):476-483. (Pubitemid 16000693)
10. Lawton MT, Kim H, McCulloch CE, Mikhak B, Young WL. A supplementary grading scale for selecting patients with brain arteriovenous malformations for surgery. Neurosurgery. 2010;66(4):702-713.
11. Stapf C. The rationale behind "A Randomized Trial ofUnruptured Brain AVMs" (ARUBA). Acta Neurochir Suppl. 2010;107(3):83-85.
12. Sonstein WJ, Kader A, Michelsen WJ, Llena JF, Hirano A, Casper D. Expression of vascular endothelial growth factor in pediatric and adult cerebral arteriovenous malformations: an immunohistochemical study. J Neurosurg. 1996;85(5): 838-845. (Pubitemid 26362148)
13. Hashimoto T, Emala CW, Joshi S, et al. Abnormal pattern ofTie-2 and vascular endothelial growth factor receptor expression in human cerebral arteriovenous malformations. Neurosurgery. 2000;47(4):910-918.
14. Uranishi R, Baev NI, Ng PY, Kim JH, Awad IA. Expression of endothelial angiogenesis receptors in human cerebrovascular malformations. Neurosurgery. 2001;48(2):359-367.
15. Hashimoto T, Lawton MT, Wen G, et al. Gene microarray analysis ofhuman brain arteriovenous malformations. Neurosurgery. 2004;54(2):410-425. (Pubitemid 38209411)
16. Chen Y, Pawlikowska L, Yao JS, et al. Interleukin-6 involvement in brain arte-riovenous malformations. Ann Neurol. 2006;59(1):72-80. (Pubitemid 43042873)
17. Chen Y, Hao Q, Kim H, et al. Soluble endoglin modulates aberrant cerebral vascular remodeling. Ann Neurol. 2009;66(1):19-27.
18. Jabbour MN, Elder JB, Samuelson CG, et al. Aberrant angiogenic characteristics of human brain arteriovenous malformation endothelial cells. Neurosurgery. 2009;64(1):139-148.
19. Christopherson KS, Ullian EM, Stokes CCA, et al. Thrombospondins are as-trocyte-secreted proteins that promote CNS synaptogenesis. Cell. 2005; 120(3):421-433. (Pubitemid 40222435)
20. Liauw J, Hoang S, Choi M, et al. Thrombospondins 1 and 2 are necessary for synaptic plasticity and functional recovery after stroke. J Cereb Blood Flow Metab. 2008;28(10):1722-1732.
21. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med. 2002;6(1):1-12. (Pubitemid 44133979)
22. Bornstein P. Thrombospondins as matricellular modulators ofcell function.J Clin Invest. 2001;107(8):929-934. (Pubitemid 32323400)
23. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol. 2004; 36(6):961-968. (Pubitemid 38528716)
24. Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci. 2008;65(5):700-712.
25. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation oftumor angiogenesis by thrombospondin-1. Biochim Biophys Acta. 2006;1765(2):178-188.
26. Zubac DP, Bostad L, Kihl B, Seidal T, Wentzel-Larsen T, Haukaas SA. The expression ofthrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol. 2009;182(5):2144-2149.
27. Pour L, Svachova H, Adam Z, et al. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol. 2010;89(4):385-389.
28. Volpert OV, Pili R, Sikder HA, et al. Id1 regulates angiogenesis through tran-scriptional repression ofthrombospondin-1. Cancer Cell. 2002;2(6):473-483. (Pubitemid 41043952)
29. Long AD, Mangalam HJ, Chan BY, Tolleri L, Hatfield GW, Baldi P. Improved statistical inference from DNA microarray data using analysis of variance and a Bayesian statistical framework. Analysis of global gene expression in Escherichia coli K12. J Biol Chem. 2001;276(23):19937-19944.
30. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100(16):9440-9445. (Pubitemid 37033947)
31. Arnaoutova I, Kleinman HK. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc. 2010;5(4):628-635.
32. Xu B, Wu YQ, Huey M, et al. Vascular endothelial growth factor induces ab-normal microvasculature in the endoglin heterozygous mouse brain. J Cereb Blood Flow Metab. 2004;24(2):237-244. (Pubitemid 38199117)
33. Rhoten RL, Comair YG, Shedid D, Chyatte D, Simonson MS. Specific repression of the preproendothelin-1 gene in intracranial arteriovenous malformations. J Neurosurg. 1997;86(1):101-108. (Pubitemid 27009980)
34. 1 integrins. J Cell Biol. 2005;168(4):643-653. (Pubitemid 40271029)
35. Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck NP. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6(1):41-48. (Pubitemid 30048524)
36. Dawson DW, Pearce SFA, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the in vitro inhibitory effects ofthrombospondin-1 on endothelial cells. J Cell Biol. 1997;138(3):707-717. (Pubitemid 27349849)
37. Oganesian A, Armstrong LC, Migliorini MM, Strickland DK, Bornstein P. Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell. 2008;19(2):563-571. (Pubitemid 351272145)
38. Yamauchi M, Imajoh-Ohmi S, Shibuya M. Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle. Cancer Sci. 2007;98(9):1491-1497. (Pubitemid 47241775)
39. Charalambous C, Chen TC, Hofman FH. Characteristics of tumor-associated endothelial cells derived from glioblastoma multiforme. Neurosurg Focus. 2006;20(4):E22-E26.
40. Calzada MJ, Zhou L, Sipes JM, et al. 0;4β1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo Circ Res. 2004;94(4):462-470. (Pubitemid 38326281)
41. 8 is associated with brain arteriovenous malformation pathogenesis. Am J Pathol. 2010;176(2):1018-1027.
42. Kim H, Pawlikowksa L, Chen Y, Su H, Yang G-Y, Young WL. Brain arterio-venous malformation biology relevant to hemorrhage and implication for thera-peutic development. Stroke. 2008;40(3 Suppl):S95-S97.
43. Leblanc GG, Golanov E, Awad IA, Young WL, Biology of Vascular Malforma-tions of the Brain NINDS Workshop Collaborators. Biology of vascular mal-formations ofthe brain. Stroke. 2009;40(12):e694-e702.
44. Zhang H, Akman HO, Smith ELP, Zhao J, Siddiqui JEM-UMAQ, Batuman OA. Cellular response to hypoxia involves signaling via Smad proteins. Blood. 2003;101(6):2253-2260. (Pubitemid 36302067)
45. Schwarte-Waldhoff I, Volpert OV, Bouck NP, et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA. 2000;97(17):9624-9629. (Pubitemid 30650826)
46. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM. Id1 proteins in cell growth and tumorigenesis. Cancer Cell. 2003;3(6):525-530. (Pubitemid 36808647)
47. Sakurai D, Tsuchiya N, Yamaguchi A, et al. Crucial role of inhibitor of DNA binding/differentiation in the vascular endothelial growth factor-induced activa-tion and angiogenic processes of human endothelial cells. J Immunol. 2004;173(9):5801-5809. (Pubitemid 39392170)
48. James D, Nam H-S, Seandel M, et al. Expansion and maintenance of human embryonic stem cell-derived endothelial cell by TGFß inhibition is Id1 dependent. Nat Biotechnol. 2010;28(2):161-166.
49. Gao D, Nolan D, McDonnell K, et al. Bone marrow-derived endothelial pro-genitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta. 2009;1796(1):33-40.
50. Desai SY, Marroni M, Cucullo L, et al. Mechanisms of endothelial survival under shear stress. Endothelium. 2002;9(2):89-102. (Pubitemid 35252017)
51. Krizanac-Bengez L, Kapural M, Parkinson F, et al. Effects oftransient loss ofshear stress on blood-brain barrier endothelium: role ofnitric oxide and IL-6. Brain Res. 2003;977(2):239-246. (Pubitemid 36782480)
52. Akakin A, Ozkan A, Akgun E, et al. Endovascular treatment increases but gamma knife radiosurgery decreases angiogenic activity of arteriovenous malformations: an in vivo experimental study using a rat cornea model. Neurosurgery. 2010;66(1):121-129.
53. Lee CZ, Yao JS, Huang Y, et al. Dose-response effect oftetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor stimulation. J Cereb Blood Flow Metab. 2006;26(9):1157-1164. (Pubitemid 44268178)
54. Lee CZ, Xue Z, Zhu Y, Yang GY, Young WL. Matrix metalloproteinase-9 in-hibition attenuates vascular endothelial growth-factor-induced intracerebral hemorrhage. Stroke. 2007;38(9):2563-2568. (Pubitemid 47329638)
55. Anderson JC, Grammer JR, Wang W, et al. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by in-hibiting angiogenesis. Cancer Biol Ther. 2007;6(3):454-462. (Pubitemid 47328316)
56. Nabors LB, Fiveash JB, Markert JM, et al. A Phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol. 2010;67(3):313-319.